GLP-1 drugs may slow aging by years

Pharmaceutical companies Eli Lilly and Novo Nordisk announced that GLP-1 weight loss drugs may also slow biological aging, reducing aging by two to three years based on blood analysis from large clinical trials. These medications, primarily used for weight loss and managing type 2 diabetes, showed evidence of slowing molecular aging indicators, suggesting they could act as geroprotectors. While the research points to potential benefits for longevity, it remains unclear if healthy individuals would experience similar effects, and side effects are acknowledged. More studies are underway to explore their impact on aging and cognitive health.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article